- Home
- AR vs AXSM Comparison
AR vs AXSM Comparison
Compare AR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AR | AXSM |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 8.6B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AR | AXSM |
|---|---|---|
| Price | $39.37 | $222.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 17 |
| Target Price | $47.13 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 4.8M | 752.5K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | 38.56 |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $5,275,823,000.00 | N/A |
| Revenue This Year | $29.74 | $57.24 |
| Revenue Next Year | $5.07 | $55.88 |
| P/E Ratio | $22.94 | ★ N/A |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $29.10 | $96.09 |
| 52 Week High | $45.75 | $234.29 |
Technical Indicators
Market Signals| Indicator | AR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 79.31 |
| Support Level | $32.86 | $148.87 |
| Resistance Level | $45.75 | N/A |
| Average True Range (ATR) | 1.21 | 10.24 |
| MACD | 0.22 | 3.71 |
| Stochastic Oscillator | 79.35 | 79.12 |
Price Performance
Historical ComparisonAbout AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2025, the company reported proven reserves of 19.1 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,442 million cubic feet of equivalent per day in 2025 at a ratio of 35% liquids and 65% natural gas.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.